

**THE SPHINGOMYELINASES: THEIR REGULATION AND ROLES IN
CARDIOVASCULAR PATHOPHYSIOLOGY**

Catherine Pavoine^{1,2} and Françoise Pecker^{1,2,3}

Running title: Sphingomyelinases in cardiovascular pathophysiology

1. INSERM, Unité U955, Créteil, F- 94010, France;

2. Université Paris12, Faculté de Médecine, UMR-S955, Créteil, F- 94010, France;

3. AP-HP, Groupe Hospitalier Henri-Mondor Albert-Chenevier, Fédération de Cardiologie,
Créteil, F-94010, France;

Correspondence to:

Françoise Pecker, INSERM, Unité U955, Créteil, F- 94010, France.

Tel: 33 1 49 81 35 34 - Fax: 33 1 48 98 09 08 -

E-mail: francoise.pecker@inserm.fr

Word count: 7455

ABSTRACT

Sphingomyelinases (SMases) hydrolyse sphingomyelin, releasing ceramide, and creating a cascade of bioactive lipids. These lipids include sphingosine and sphingosine-1-phosphate, all of which have a specific signalling capacity. SMase activation occurs in different cardiovascular system cell types, namely cardiac myocytes, endothelial and vascular smooth muscle cells, mediating cell proliferation, cell death and contraction of cardiac and vascular myocytes. Three main types of SMases contribute to cardiovascular physiology: the lysosomal and secreted acidic SMases (L- and S-ASMases, respectively) and the membrane neutral SMase (NSMase). These three enzymes have common activators, including ischaemia/reperfusion stress and proinflammatory cytokines, but they differ in their enzymatic properties and subcellular locations which determine the final effect of enzyme activation. This review focuses on the recent advances in the understanding of ASMase and NSMase pathways, and their specific contribution to cardiovascular pathophysiology. Current knowledge indicates that the inhibitors of the different SMase types are potential tools for the treatment of cardiovascular diseases. ASMase inhibitors could be tools against post-ischaemia reperfusion injury, and in the treatment of atherosclerosis. NSMase inhibitors could be tools for the treatment of atherosclerosis, heart failure and age-related decline in vasomotion. However, the design of bioavailable and more specific SMase-type inhibitors remains a challenge.

INTRODUCTION

Once considered an inert constituent of mammalian cell membranes, sphingomyelin (SM, ceramide-phosphocholine) now emerges as the starting point of a complex sphingolipid signalling pathway. Sphingomyelinases (SMases; EC 3.1.4.12), which hydrolyse SM into phosphocholine and ceramide¹, are key regulatory enzymes of this pathway. In fact, ceramide not only exerts multiple biological effects *per se*, but also elicits the production in cascade of other bioactive sphingolipids, including sphingosine and sphingosine-1-phosphate (S1P)^{2,3}.

According to their optimum pH (alkaline, acid and neutral) SMases isoforms can be divided into three groups, and are further distinguished by their primary structure, localization and cation dependence⁴. Alkaline SMase expression is confined to the intestinal mucosa in many species; in humans, it is also found in the bile and liver⁵. Acid SMases (ASMases) and membrane neutral SMases (NSMases), however, are crucially involved in cardiovascular physiology and pathophysiology^{6,7}. The regulation and roles of sphingolipids and SMases in cell signalling and pathophysiology have been documented in excellent recent reviews by Levade and colleagues⁸, Marchesini and Hannun⁹, Holland and Summers¹⁰ and Smith and Schuchman¹¹. In this review, after a brief overview on the central role of ceramide in the complex sphingolipid metabolic and signalling network, we focus on recent advances concerning mechanisms of regulation, and the roles of ASMases and NSMases in the cardiovascular field.

CERAMIDE

Sphingomyelinases ensure ceramide production. The term "ceramide" refers to a family of at least 50 distinct, highly hydrophobic molecules containing a variable length fatty acid (2-28 carbons) linked to sphingosine or a related long chain base. Ceramide metabolism generates a cascade of bioactive lipids, all of which carry a specific signalling capacity. This sphingolipid signalling network is found in the different cardiovascular system cell types and is critically

involved in cell proliferation, cell death and cardiac myocyte (CM) and vascular smooth muscle cell (VSMC) contraction⁸.

Most enzymes involved in sphingolipid metabolism show specific subcellular localisation. The lysosomal ASMase, L-ASMase, localises primarily in the endolysosomal compartment, but under certain conditions it can relocate to the outer leaflet of the plasma membrane^{4,9}. NSMase has been identified in the endoplasmic reticulum and the Golgi apparatus^{4,12}, but would also localise in the inner leaflet of the plasma membranes^{2,13,14}. Ceramide levels may therefore be regulated by distinct mechanisms and in distinct compartments. Ceramide is converted by ceramidase into sphingosine, which in turn is phosphorylated by sphingosine kinase into S1P. These lipids exert opposite biological effects: ceramide and sphingosine are primarily antiproliferative and pro-apoptotic, whereas S1P promotes cell growth and counteracts apoptotic stimuli. As a result, the ratio between ceramide plus sphingosine and the S1P level (also referred to as the ceramide/S1P rheostat) is the true determinant of a cell's fate, rather than the individual ceramide, sphingosine or S1P levels¹⁵.

In addition to its production via sphingomyelin hydrolysis, ceramide can be created by a "de novo" pathway, the first and rate-limiting step of which is the condensation of palmitoyl coA with serine by serine palmitoyltransferase^{3,16}. Using pharmacologic and genetic methods targeting the serine palmitoyltransferase, Park and colleagues have shown that the *de novo* ceramide pathway is involved not only in the pathogenesis of lipotoxic cardiomyopathy¹⁷ but also in the formation of atherogenic plaques¹⁸. These authors further showed that myriocin, a serine palmitoyltransferase inhibitor, lowered plasma sphingolipids and atherogenic plasma lipids, leading to the regression of pre-existing atherosclerotic lesions and the formation of a stable plaque phenotype. This implies that the regulation of sphingolipid biosynthesis may have clinical applications in the treatment of advanced atherosclerosis¹⁸.

SMASE ASSAYS

SMase activity is generally not difficult to measure, although it requires a certain amount of biological material. It can be assayed *in vivo* through labelling of cells with a radioactive SM precursor, or *in vitro* using either radiolabelled SM or chromogenic, coloured or fluorescent

derivatives of natural SM¹⁹. Recent colorimetric or fluorimetric kits also allow indirect measurements of phosphocholine released upon SMase activity. The activities of the three SMase types are determined using different buffers at alkaline, neutral or acidic pH^{20,21}.

DISTINCT SMASES: ASMASES AND NSMASES

In 1963, Gatt and colleagues described an SMase activity, active at acidic pH²². By the late 1960s, deficiency of ASMase was reported to be responsible for the rare recessively inherited lysosomal storage disorder, Niemann-Pick disease (NPD)²³. The cDNA and gene encoding ASMase (designated *Smpd1*) were cloned in 1989 and 1992, respectively^{24,25}. A secreted form of the ASMase, also encoded by the *Smpd1* gene, was identified in foetal bovine serum²⁶. The total preservation of Mg²⁺-dependent NSMase activity with an optimum pH of 7.4 in tissues from NPD patients²⁷ and in ASMase knockout mice²⁸ proved that ASMases and NSMases were separate gene products⁹. Three NSMase genes (*Smpd2, 3 and 4*) have now been cloned^{29,30,12}. Mice deficient for NSMase1 gene (*Smpd2*) do not show any functional phenotype³¹ and the *in vivo* role of NSMase1 as a sphingomyelin hydrolysing enzyme remains unclear³². The NSMase2 gene (*Smpd3*) is ubiquitously expressed, and is essential in growth and skeletal development³³. Finally, the recently cloned NSMase3 (encoded by the *Smpd4 gene*) belongs to the family of C-tail-anchored membrane proteins, and is an integral part of TNF-alpha receptor type 1 (TNFR1) and adaptor protein FAN (factor associated with NSMase activation) signalling¹². Interestingly, NSMase3 mRNA is highly expressed in cardiac tissues, raising the possibility of specific roles of NSMase3 in cardiac function and pathology¹².

ASMASE ACTIVITY: ONE GENE, TWO ENZYMES, THREE SITES OF ACTION

ASMase activity in ischaemia/reperfusion injury

Many studies have examined ASMase activity without discriminating between the contribution of the two enzyme isoforms, the lysosomal ASMase (L-ASMase), and the secreted ASMase (S-ASMase). This is particularly true in studies dealing with ischaemia/reperfusion

injury, but it does not lessen their significance. ASMase activity occurs in all cardiac tissue examined in the rat, the mouse and in humans^{28,34}. It fulfils an essential housekeeping function in lysosomes, as shown by the multi organ abnormalities in NPD, which results from lysosomal sphingomyelin accumulation due to ASMase deficiency^{23,35}. ASMase activity also contributes to cellular signalling in response to external stress stimuli including ischaemia/reperfusion and stimulation of diverse receptors in the TNF receptor superfamily.

Prolonged myocardial ischaemia inevitably results in cell death, and the duration of ischaemia is a primary determinant of infarct size. Reoxygenation through reperfusion reduces ischaemic damage, but also triggers additional cell death³⁶. Preconditioning, which consists of applying transient episodes of ischaemia/reperfusion before the sustained ischaemic event, protects the heart from ischaemia/reperfusion injury³⁷ by limiting apoptosis, both *in vitro*³⁸ and *in vivo*³⁹. Post-conditioning has recently emerged as a more relevant clinical strategy; it consists of applying transient episodes of ischaemia/reperfusion after the sustained ischaemic event, instead of before^{40,41}. Pre- and post-conditioning cardioprotective strategies may rely on a similar signalling pathway in the reperfused heart⁴².

Several studies suggest a causal relationship between the increase in ceramide content and CM death in the post-ischaemic reperfused rat heart⁴³⁻⁴⁵. Argaud and colleagues⁴⁶ have shown that benefits of preconditioning are related to reduced cardiac ceramide content. The ASMase inhibitor, tricyclodecan 9 y-xanthate (D609), administered before the ischaemic period, reproduces preconditioning protection, proving the contribution of ASMase activity in the ischaemia-induced cell death⁴⁶. However, Lecour and colleagues⁴⁷ report that preconditioning with TNF-alpha, that is likely to activate ASMase and/ or NSMase⁹, also exerts an ischaemic preconditioning-like protection. TNF-alpha protection is reproduced by the cell-permeable C2-ceramide. The discrepancy between these two reports probably illustrates the multiple responses that ceramide may mediate depending on its subcellular location, which determines its proximal targets and downstream metabolism³. It may be that ASMase activation triggered by the ischaemic preconditioning provides ceramide integral to a cell death pathway, whereas TNF-alpha and cell permeable C2-ceramide release ceramide for the ceramidase/ sphingosine kinase metabolism cascade. In fact, the ceramidase inhibitor N-oleoylethanolamine (NOE) hinders the preconditioning-like protection provided by TNF-alpha or C2-ceramide, but does not

hinder the protection induced by ischaemic preconditioning⁴⁷.

Using the tricyclic antidepressant inhibitor desipramine (a potent ASMase inhibitor), Das and colleagues^{48,49} document the two-edged role of ceramide, mediating protection in ischaemic preconditioning but promoting apoptosis after the ischaemia/reperfusion event. Thus, ASMase-mediated accumulation of ceramide in the ischaemic heart is causally related with apoptosis and cardiac dysfunction. In contrast, ischaemic preconditioning leads to a limited accumulation of ceramide in the ischaemic/reperfused heart, along with an increase in S1P content⁴⁸. The connection is seen between ceramide generated in lipid rafts during ischaemia/reperfusion, and the increased association of endothelial nitric oxide synthase (eNOS) with caveolin-1, which makes endothelial NO unavailable to the ischaemic heart⁴⁹. It is worth noting that deletion of the sphingosine kinase 1 gene abolishes the cardioprotection produced by either ischaemic preconditioning or ischaemic postconditioning^{50,51}.

The lysosomal (L) and secreted (S) isoforms of ASMase

In the late 90's, Tabas and coworkers⁵² found that, *via* differential protein trafficking, the single *Smpd1* gene and the single ≈ 75 kDa protein precursor can generate the two functionally distinct forms of ASMases, L-ASMase and S-ASMase. Lysosomal ASMase is a ≈ 70 kDa glycoprotein with oligosaccharide side chains containing mannose-6-phosphate residues, typical of lysosomal proteins. Its *in vitro* pH optimum is between 4.5 and 5, and sphingomyelin accumulation in the lysosomes of NPD patients further support its classification as a lysosomal protein⁵³. Secreted-ASMase contains complex N-linked oligosaccharides. Both L- and S-ASMase isoforms require Zn^{2+} for their activity; L-ASMase is tightly bound to Zn^{2+} and does not need exogenous Zn^{2+} to attain full activity, whereas S-ASMase requires exogenous Zn^{2+} for its optimum activation (reviewed in^{11,54}).

Human coronary artery endothelial cells (ECs) secrete large amounts of S-ASMase in an active, Zn^{2+} -complexed form that is stimulated by certain inflammatory cytokines, including interferon-gamma (IFN-gamma) and interleukin-1beta (IL1-beta)⁵⁵. Increase in S-ASMase is essentially related to a decrease in L-ASMase, supporting the hypothesis that the mechanism of cytokine-induced increase in S-ASMase relies on the shunting of the common precursor away

from the lysosomal trafficking pathway and into the Golgi secretory pathway^{54,55}.

L-ASMase and vascular tone

In human lymphocytes, Grassmé and colleagues⁵⁶ were the first to show that diverse receptors, belonging to the TNF receptor superfamily and mediating apoptosis, triggered L-ASMase translocation from lysosomes to the extracellular surface of the cell membrane. The translocated L-ASMase localises to sphingolipid-rich membrane lipid rafts and releases extracellularly orientated ceramide. This allows the formation of larger ceramide-enriched platforms, which serve to trap and cluster the receptors determining the initiation of apoptosis signalling⁵⁷. The mechanism described relies on the phosphorylation of L-ASMase by PKCdelta⁵⁸ (or an ASMase coming from a cytosolic pool¹¹). L-ASMase-dependent formation of ceramide-enriched lipid macrodomains in VSMCs and EC contributes to FasL-induced impairment of the vasodilator response^{59,60} and muscarinic-1 receptor-mediated coronary artery constriction⁶¹, which are both major aggravating factors in atherosclerosis.

S-ASMase in atherosclerosis

Both proliferation and death of VSMCs contribute to the progression of the atherosclerotic lesions. Levade and colleagues⁶² were the first to reveal the possible involvement of the sphingomyelin/ ceramide pathway in atherogenesis, through a mitogenic effect on VSMCs. ECs, which cover the atherosclerotic lesions, secrete S-ASMase. Enzyme secretion is enhanced by atherogenic pro-inflammatory cytokines⁵⁵. Secreted-ASMase hydrolyses sphingomyelin to ceramide on the surface of atherogenic lipoprotein particles, even at neutral pH⁶³. The resulting increase in lipoprotein ceramide promotes fusion and subendothelial aggregation of the lipoprotein particles, increasing their affinity for arterial wall proteoglycans and leading to foam cell formation⁶⁴. Studies in patients and experimental models confirm the presence of S-ASMase in atherosclerotic lesions⁶⁵, and show that the latter are significantly decreased upon pharmacological inhibition of sphingomyelin synthesis⁶⁶. Also, oxidized phospholipids that are found in atherosclerotic lesions may promote VSMC death via ASMase activation⁶⁷

Furthermore, in a recent study using two double knockout mice models (consisting of two hyperlipidaemic models of atherosclerosis crossed onto ASMase deficient mice (producing *ApoE*^{-/-}; *Asm*^{-/-} and *Ldlr*^{-/-}; *Asm*^{-/-})), Tabas and colleagues⁶⁸ showed that ASMase deficiency reduces both lesion development and arterial trapping of atherogenic lipoproteins.

S-ASMase in heart failure

In addition to neuro-hormonal activation, inflammation and oxidative stress are key components in chronic heart failure (HF) progression⁶⁹⁻⁷¹ and severity⁷²⁻⁷⁴. The ability of pro-inflammatory cytokines to trigger S-ASMase secretion from ECs^{55,75}, combined with the stimulatory effect of reactive oxygen species (ROS) on enzyme activity⁷⁶⁻⁷⁸ are possible mechanisms explaining the increase in plasma S-ASMase activity in patients with HF⁷⁹. In their pilot study, Anker and colleagues discovered that this activity is increased by 90% in patients with HF, compared with controls, and was a significant predictor of impaired survival⁷⁹. Plasma S-ASMase activity was positively related to the disease severity (assessed by the New York Heart Association functional class and peak oxygen uptake), and main clinical markers (including creatinine, uric acid, plasma TNF-alpha and sTNFR1). Impaired peripheral blood flow and vasodilator capacity is also associated with S-ASMase activation⁷⁹. This is relevant to the previously reported increase in plasma levels of TNF-alpha in heart failure patients with impaired peripheral blood flow⁸⁰, and the finding by Zhang et al⁸¹ that desipramine neutralises the inhibitory effect of TNF-alpha on endothelium-dependent vasorelaxation.

MULTIPLE NSMASES

Clarke and Hannun recently reviewed overall NSMase properties and physiological roles^{32,82}. NSMase hydrolyses a SM pool located in the inner leaflet of the plasma membrane^{13,14}. In the different cardiovascular system cell types, several external stimuli trigger NSMase activation, giving the enzyme a major regulatory role in ceramide-dependent apoptosis and cell growth. The mammalian NSMase genes have been cloned only recently and specific pharmacological tools are lacking. As a result, the distinct roles of NSMase isoforms in

cardiovascular disorders are not yet well defined.

NSMase signalling pathways

In isolated CM, NSMase mediates apoptosis elicited by TNF-alpha^{83,84} or IL-1beta⁸⁵. TNF-alpha activates the NSMase3 isoform through its recruitment to TNFR1 by the FAN adapter protein^{86,87}. Inhibition by the tripeptide glutathione (L-γ-glutamyl-cysteinyl-glycine) is a common feature of NSMase isoforms 1 and 3^{30,88}. In fact, we have shown that cellular glutathione determines NSMase responsiveness to TNF-alpha^{89,90}, and that the enzyme's activation in failing rat and human hearts is related to a deficiency in glutathione^{91,92}.

In cultured VSMC, apolipoprotein C-1 (apoC-1)-enriched high-density lipoproteins (HDLs) stimulate NSMase, triggering an apoptotic response *via* the release of cytochrome c from mitochondria and caspase-3 activation⁹³. Oxidised low-density lipoproteins (oxLDLs) and TNF-alpha also stimulate NSMase in VSMCs^{94,95}. However, these stimuli do not trigger apoptosis, but instead contribute to VSMC proliferation resulting from the metabolism of ceramide into S1P, and downstream activation of ERK1/2 MAPKinases^{94,95}. In cultured VSMC and using the small interfering RNA strategy (siRNA), Auge et al. demonstrated both, the specific involvement of the NSMase2 isoform in the mitogenic effect of ROS⁹⁶ and oxLDL⁹⁷, and the process of NSMase2 activation that relies on a proteolytic cascade involving furin/ MT1-MPP/MMP-2 proteases^{96,97}. This MMP/ NSMase2 pathway also drives the mitogenic effect of TNF-alpha on VSMC⁹⁵.

In cultured bovine aortic EC, the cellular response to mechanical stimulation is inhibited by the NSMase inhibitor scyphostatin, and is reproduced by addition of exogenous bacterial NSMase or ceramide¹⁴. As Schnitzer and colleagues discovered, using microvascular lung EC, the mechanoactivation signalling pathway relies on ceramide generation in caveolae, and on eNOS phosphorylation and activation^{14,98,99}. This is in agreement with a study in isolated arteries showing that exogenous bacterial NSMase triggers vasorelaxation via eNOS phosphorylation and activation, independently of raised intracellular Ca²⁺ level¹⁰⁰. In contrast, NSMase activation in ageing rat arteries is related to ceramide-activated protein phosphatase 2A activity and subsequent decrease in eNOS phosphorylation and activation, leading to a loss

of vasomotor function¹⁰¹. Recently, Smith et al.¹⁰² (commented in¹⁰³) further showed that lipoic acid supplementation of isolated aortic rings reversed age-related loss of endothelial glutathione, leading to reduced NSMase activation and ceramide level in the endothelium and improved endothelial NO-dependent vasomotor function.

NSMase in ischaemia/reperfusion

Early NSMase activation in isolated CM in response to hypoxia/reoxygenation¹⁰⁴ is consistent with the reported deficiency in cardiac glutathione (its cellular inhibitor) following ischaemia/reperfusion in isolated hearts or *in vivo*¹⁰⁵⁻¹⁰⁸. In isolated CM, NSMase/sphingosine pathway determines the apoptotic response to hypoxia/reoxygenation^{104,109} or TNF-alpha^{83,87} that involves the impairment of the mitochondrial function¹¹⁰ and/or the activation of caspases^{92,111}. In addition, the NSMase/sphingosine pathway promotes the negative effect on CM contraction triggered by TNF-alpha^{84,112} or IL1-beta⁸⁵. Taken together, these *in vitro* findings indicate the deleterious consequences of NSMase/sphingosine pathway activation on CM survival and functioning, and predict a critical role for NSMase in the development of cardiac failure.

NSMase in heart failure

Oxidative stress and inflammation are major interrelated contributors to the development of HF. Glutathione contributes to many metabolic cell functions, in particular cell defence against oxidative stress, and is essential to cell survival. In its reduced form (GSH), glutathione serves as a cofactor to glutathione peroxidase to reduce intracellular ROS, being oxidized to the disulfide-linked dimer (GSSG). In situations involving prolonged oxidative stimuli, GSSG cannot be recycled, and is pumped out of the cell such that the cellular glutathione content decreases if glutathione is not resynthesized through other pathways. In the failing heart, prolonged oxidative stress creates cardiac glutathione deficiency; this deficiency, together with TNF-alpha upregulation, causes NSMase activation^{91,92}. However, in animal models, glutathione repletion (produced by oral administration of a precursor of glutathione synthesis, N-acetylcysteine

(NAC)) blunts the activation of the NSMase/caspase-3 apoptotic pathway, regresses fibrosis and inflammation and improves cardiac function^{91,92}. Treatment with NAC for 3 days replenishes cardiac glutathione only partially, but is enough to dampen down NSMase activity and related caspase-3 activation to control values. This suggests the early involvement of NSMase inhibition in NAC-induced cardiac recovery⁹². The regression of cardiac fibrosis seen with NAC treatment that may rely not only on the decrease in ceramide-induced CM apoptosis, but also on the impairment of S1P-induced cardiac myofibroblast activation¹¹³.

NSMase in atherosclerosis

Apoptosis of VSMCs is a critical event in the rupture of the atherosclerotic plaque, leading to thrombosis, myocardial infarction, and possible death. *In vitro* studies highlight the ability of apoC-1 enriched HDLs to induce VSMC death via NSMase activation⁹³. In patients, the apoC-1 content of lipoprotein remnants appears as an early marker of coronary artery disease risk¹¹⁴. Using a Watanabe hyperlipidaemic rabbit model of plaque rupture and employing novel non-invasive advanced high-resolution MRI techniques, Steen and colleagues¹¹⁵, further established the colocalisation of apoC-1, ceramide, caspase-1 and 3 in regions of plaque rupture, thus pointing to an *in vivo* relevance of the *in vitro* findings.

Via NSMase activation, oxLDLs induce cultured VSMC proliferation^{94,97}, which *in situ* contributes to the formation and progression of atherosclerotic lesions. Ox-LDLs are present in both animal and human atherosclerotic lesions and trigger the progression of atherosclerosis and plaque rupture¹¹⁶.

CONCLUSION: THERAPEUTIC PERSPECTIVES

It is now clear that stress-induced activation of ASMases and NSMases, may contribute in different ways to the development of cardiac and vascular dysfunction (Table 1).

ASMase deficiency in NPD leads to lipid abnormalities that may be associated with early atherosclerotic heart disease¹¹⁷. Nevertheless, S-ASMase activation in atherosclerotic lesions contributes to the progression of the lesion^{64,68}. These results imply therefore that therapy for

atherosclerosis would have specifically target the inhibition of the S-ASMase isoform of ASMase. This is further supported by the demonstration that in a genetically engineered mouse model, where S-ASMase was suppressed but L-ASMase was preserved, there was no development of central nervous system dysfunction or systemic disease that occur in complete ASMase deficiency¹¹⁸. However, the only currently available ASMase inhibitors are nonspecific. They comprise the tricyclic antidepressants imipramine and desipramine^{48,49}, D609⁴⁶, NB6¹¹⁹, L-carnitine¹²⁰ and the multi-drug resistance reversal agent SR33557, which also blocks Ca²⁺ channels¹²¹.

NSMase activation is associated with heart failure progression and endothelial dysfunction. The most studied specific inhibitors of NSMase include scyphostatin¹²² and GW4869¹²³ which inhibit vascular EC NSMase activity when added either to the cell medium or to the isolated vessel perfusate^{14,101}. However, *in vivo*, the effectiveness of scyphostatin has only been documented in a rat model of paw oedema¹²².

Another new nonspecific ASMase and NSMase inhibitor (SMA-7, a difluoromethylene analogue of sphingomyelin) reduces colitis in mice when given orally¹²⁴. Such a lack of specificity may be advantageous in pathological situations with concomitant activation of ASMase and NSMase. In contrast, glutathione specifically inhibits NSMase, and cellular glutathione content is a major determinant of cellular NSMase activity^{88,125}. Ageing and most of the chronic inflammatory diseases are featured by systemic and/or tissue glutathione deficiency. Several studies in animal models and patients suggest that oral or intra-peritoneal administration of NAC or lipoic acid (which are both antioxidant molecules, but are above all precursors of glutathione) restored tissue glutathione. In HF, as in age-related decline in vasomotion, the benefits of NAC or lipoic acid treatment are related to NSMase inhibition^{92,102}.

In conclusion, SMases are potential targets for drug development in the treatment of atherosclerosis, heart failure and age-related cardiovascular diseases. In particular, ASMase inhibitors could be tools against post-ischaemia reperfusion injury, and in the treatment of atherosclerosis, bearing in mind that S-ASMase might be a preferable target than L-ASMase^{64,68,118}. NSMase inhibitors could be tools for the treatment of atherosclerosis, heart failure and age-related decline in vasomotion. Pharmacological studies have already identified possible therapeutic substances targeting NSMase, such as NAC and lipoic acid to be used to

complement current treatments for heart failure or decline in vasomotion. However, these should be further developed by taking advantage of new experimental models and molecular biology techniques (such as genetically modified mice and siRNA) that should allow a better understanding of the SMase isoforms specifically involved in the different disease pathways and the design of bioavailable and more specific SMase-type inhibitors.

FUNDING

This work was supported by the Institut National de la Santé et de la Recherche Médicale, the Assistance Publique des Hôpitaux de Paris (as a Contrat d'Interface to F.P.), the Université Université Paris-Val-de-Marne and the Agence Nationale de la Recherche.

ACKNOWLEDGMENTS

Catriona Holmes provided editorial assistance.'

CONFLICT OF INTEREST: none declared

REFERENCES

1. Kanfer JN, Young OM, Shapiro D, Brady RO. The metabolism of sphingomyelin. I. Purification and properties of a sphingomyelin-cleaving enzyme from rat liver tissue. *J Biol Chem* 1966;**241**:1081-1084.
2. Tani M, Ito M, Igarashi Y. Ceramide/sphingosine/sphingosine 1-phosphate metabolism on the cell surface and in the extracellular space. *Cell Signal* 2007;**19**:229-237.
3. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. *Nat Rev Mol Cell Biol* 2008;**9**:139-150.
4. Goni FM, Alonso A. Sphingomyelinases: enzymology and membrane activity. *FEBS Lett* 2002;**531**:38-46.
5. Duan RD. Alkaline sphingomyelinase: an old enzyme with novel implications. *Biochim Biophys Acta* 2006;**1761**:281-291.
6. Linardic CM, Hannun YA. Identification of a distinct pool of sphingomyelin involved in the sphingomyelin cycle. *J Biol Chem* 1994;**269**:23530-23537.
7. Andrieu N, Salvayre R, Levade T. Comparative study of the metabolic pools of sphingomyelin and phosphatidylcholine sensitive to tumor necrosis factor. *Eur J Biochem* 1996;**236**:738-745.
8. Levade T, Auge N, Veldman RJ, Cuvillier O, Negre-Salvayre A, Salvayre R. Sphingolipid mediators in cardiovascular cell biology and pathology. *Circ Res* 2001;**89**:957-968.
9. Marchesini N, Hannun YA. Acid and neutral sphingomyelinases: roles and mechanisms of regulation. *Biochem Cell Biol* 2004;**82**:27-44.
10. Holland WL, Summers SA. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. *Endocr Rev* 2008;**29**:381-402.
11. Smith EL, Schuchman EH. The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseases. *Faseb J* 2008;**22**:3419-3431.

12. Krut O, Wiegmann K, Kashkar H, Yazdanpanah B, Kronke M. Novel tumor necrosis factor-responsive mammalian neutral sphingomyelinase-3 is a C-tail-anchored protein. *J Biol Chem* 2006;**281**:13784-13793.
13. Andrieu-Abadie N, Levade T. Sphingomyelin hydrolysis during apoptosis. *Biochim Biophys Acta* 2002;**1585**:126-134.
14. Czarny M, Schnitzer JE. Neutral sphingomyelinase inhibitor scyphostatin prevents and ceramide mimics mechanotransduction in vascular endothelium. *Am J Physiol Heart Circ Physiol* 2004;**287**:H1344-1352.
15. Alewijnse AE, Peters SL, Michel MC. Cardiovascular effects of sphingosine-1-phosphate and other sphingomyelin metabolites. *Br J Pharmacol* 2004;**143**:666-684.
16. Merrill AH, Jr. De novo sphingolipid biosynthesis: a necessary, but dangerous, pathway. *J Biol Chem* 2002;**277**:25843-25846.
17. Park TS, Hu Y, Noh HL, Drosatos K, Okajima K, Buchanan J *et al.* Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. *J Lipid Res* 2008;**49**:2101-2112.
18. Park TS, Rosebury W, Kindt EK, Kowala MC, Panek RL. Serine palmitoyltransferase inhibitor myriocin induces the regression of atherosclerotic plaques in hyperlipidemic ApoE-deficient mice. *Pharmacol Res* 2008;**58**:45-51.
19. Loidl A, Claus R, Deigner HP, Hermetter A. High-precision fluorescence assay for sphingomyelinase activity of isolated enzymes and cell lysates. *J Lipid Res* 2002;**43**:815-823.
20. Duan RD, Nilsson A. Sphingolipid hydrolyzing enzymes in the gastrointestinal tract. *Methods Enzymol* 2000;**311**:276-286.
21. Liu F, Cheng Y, Wu J, Tauschel HD, Duan RD. Ursodeoxycholic acid differentially affects three types of sphingomyelinase in human colon cancer Caco 2 cells. *Cancer Lett* 2006;**235**:141-146.
22. Gatt S. Enzymic Hydrolysis and Synthesis of Ceramides. *J Biol Chem* 1963;**238**:3131-3133.
23. Brady RO, Kanfer JN, Mock MB, Fredrickson DS. The metabolism of sphingomyelin. II. Evidence of an enzymatic deficiency in Niemann-Pick disease. *Proc Natl Acad Sci U S A* 1966;**55**:366-369.

24.Quintern LE, Schuchman EH, Levran O, Suchi M, Ferlinz K, Reinke H *et al.* Isolation of cDNA clones encoding human acid sphingomyelinase: occurrence of alternatively processed transcripts. *Embo J* 1989;**8**:2469-2473.

25.Schuchman EH, Levran O, Pereira LV, Desnick RJ. Structural organization and complete nucleotide sequence of the gene encoding human acid sphingomyelinase (SMPD1). *Genomics* 1992;**12**:197-205.

26.Spence MW, Byers DM, Palmer FB, Cook HW. A new Zn²⁺-stimulated sphingomyelinase in fetal bovine serum. *J Biol Chem* 1989;**264**:5358-5363.

27.Levade T, Gatt S, Maret A, Salvayre R. Different pathways of uptake and degradation of sphingomyelin by lymphoblastoid cells and the potential participation of the neutral sphingomyelinase. *J Biol Chem* 1991;**266**:13519-13529.

28.Horinouchi K, Erlich S, Perl DP, Ferlinz K, Bisgaier CL, Sandhoff K *et al.* Acid sphingomyelinase deficient mice: a model of types A and B Niemann-Pick disease. *Nat Genet* 1995;**10**:288-293.

29.Hofmann K, Tomiuk S, Wolff G, Stoffel W. Cloning and characterization of the mammalian brain-specific, Mg²⁺-dependent neutral sphingomyelinase. *Proc Natl Acad Sci U S A* 2000;**97**:5895-5900.

30.Tomiuk S, Hofmann K, Nix M, Zumbansen M, Stoffel W. Cloned mammalian neutral sphingomyelinase: functions in sphingolipid signaling? *Proc Natl Acad Sci U S A* 1998;**95**:3638-3643.

31.Zumbansen M, Stoffel W. Neutral sphingomyelinase 1 deficiency in the mouse causes no lipid storage disease. *Mol Cell Biol* 2002;**22**:3633-3638.

32.Clarke CJ, Snook CF, Tani M, Matmati N, Marchesini N, Hannun YA. The extended family of neutral sphingomyelinases. *Biochemistry* 2006;**45**:11247-11256.

33.Stoffel W, Jenke B, Holz B, Binczek E, Gunter RH, Knifka J *et al.* Neutral sphingomyelinase (SMPD3) deficiency causes a novel form of chondrodysplasia and dwarfism that is rescued by Col2A1-driven smpd3 transgene expression. *Am J Pathol* 2007;**171**:153-161.

34.Spence MW, Burgess JK, Sperker ER. Neutral and acid sphingomyelinases: somatotopographical distribution in human brain and distribution in rat organs. A possible relationship with the dopamine system. *Brain Res* 1979;**168**:543-551.

35. Schneider PB, Kennedy EP. Sphingomyelinase in normal human spleens and in spleens from subjects with Niemann-Pick disease. *J Lipid Res* 1967;**8**:202-209.
36. Garcia-Dorado D, Vinten-Johansen J, Piper HM. Bringing preconditioning and postconditioning into focus. *Cardiovasc Res* 2006;**70**:167-169.
37. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. *Circulation* 1986;**74**:1124-1136.
38. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. *J Clin Invest* 1994;**94**:1621-1628.
39. Piot CA, Martini JF, Bui SK, Wolfe CL. Ischemic preconditioning attenuates ischemia/reperfusion-induced activation of caspases and subsequent cleavage of poly(ADP-ribose) polymerase in rat hearts in vivo. *Cardiovasc Res* 1999;**44**:536-542.
40. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA *et al*. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. *Am J Physiol Heart Circ Physiol* 2003;**285**:H579-588.
41. Thibault H, Piot C, Staat P, Bontemps L, Sportouch C, Rioufol G *et al*. Long-term benefit of postconditioning. *Circulation* 2008;**117**:1037-1044.
42. Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: united at reperfusion. *Pharmacol Ther* 2007;**116**:173-191.
43. Bielawska AE, Shapiro JP, Jiang L, Melkonyan HS, Piot C, Wolfe CL *et al*. Ceramide is involved in triggering of cardiomyocyte apoptosis induced by ischemia and reperfusion. *Am J Pathol* 1997;**151**:1257-1263.
44. Cordis GA, Yoshida T, Das DK. HPTLC analysis of sphingomyelin, ceramide and sphingosine in ischemic/reperfused rat heart. *J Pharm Biomed Anal* 1998;**16**:1189-1193.
45. Beresewicz A, Dobrzyn A, Gorski J. Accumulation of specific ceramides in ischemic/reperfused rat heart; effect of ischemic preconditioning. *J Physiol Pharmacol* 2002;**53**:371-382.
46. Argaud L, Prigent AF, Chalabreysse L, Loufouat J, Lagarde M, Ovize M. Ceramide in the antiapoptotic effect of ischemic preconditioning. *Am J Physiol Heart Circ Physiol* 2004;**286**:H246-251.

47. Lecour S, Smith RM, Woodward B, Opie LH, Rochette L, Sack MN. Identification of a novel role for sphingolipid signaling in TNF alpha and ischemic preconditioning mediated cardioprotection. *J Mol Cell Cardiol* 2002;**34**:509-518.
48. Cui J, Engelman RM, Maulik N, Das DK. Role of ceramide in ischemic preconditioning. *J Am Coll Surg* 2004;**198**:770-777.
49. Der P, Cui J, Das DK. Role of lipid rafts in ceramide and nitric oxide signaling in the ischemic and preconditioned hearts. *J Mol Cell Cardiol* 2006;**40**:313-320.
50. Jin ZQ, Karliner JS, Vessey DA. Ischaemic postconditioning protects isolated mouse hearts against ischaemia/reperfusion injury via sphingosine kinase isoform-1 activation. *Cardiovasc Res* 2008;**79**:134-140.
51. Jin ZQ, Zhang J, Huang Y, Hoover HE, Vessey DA, Karliner JS. A sphingosine kinase 1 mutation sensitizes the myocardium to ischemia/reperfusion injury. *Cardiovasc Res* 2007;**76**:41-50.
52. Schissel SL, Schuchman EH, Williams KJ, Tabas I. Zn²⁺-stimulated sphingomyelinase is secreted by many cell types and is a product of the acid sphingomyelinase gene. *J Biol Chem* 1996;**271**:18431-18436.
53. Fowler S. Lysosomal localization of sphingomyelinase in rat liver. *Biochim Biophys Acta* 1969;**191**:481-484.
54. Tabas I. Secretory sphingomyelinase. *Chem Phys Lipids* 1999;**102**:123-130.
55. Marathe S, Schissel SL, Yellin MJ, Beatini N, Mintzer R, Williams KJ *et al.* Human vascular endothelial cells are a rich and regulatable source of secretory sphingomyelinase. Implications for early atherogenesis and ceramide-mediated cell signaling. *J Biol Chem* 1998;**273**:4081-4088.
56. Grassme H, Jekle A, Riehle A, Schwarz H, Berger J, Sandhoff K *et al.* CD95 signaling via ceramide-rich membrane rafts. *J Biol Chem* 2001;**276**:20589-20596.
57. Gulbins E. Regulation of death receptor signaling and apoptosis by ceramide. *Pharmacol Res* 2003;**47**:393-399.
58. Zeidan YH, Wu BX, Jenkins RW, Obeid LM, Hannun YA. A novel role for protein kinase Cdelta-mediated phosphorylation of acid sphingomyelinase in UV light-induced mitochondrial injury. *Faseb J* 2008;**22**:183-193.

59. Jin S, Yi F, Zhang F, Poklis JL, Li PL. Lysosomal Targeting and Trafficking of Acid Sphingomyelinase to Lipid Raft Platforms in Coronary Endothelial Cells. *Arterioscler Thromb Vasc Biol* 2008.
60. Zhang AY, Yi F, Jin S, Xia M, Chen QZ, Gulbins E *et al.* Acid sphingomyelinase and its redox amplification in formation of lipid raft redox signaling platforms in endothelial cells. *Antioxid Redox Signal* 2007;**9**:817-828.
61. Jia SJ, Jin S, Zhang F, Yi F, Dewey WL, Li PL. Formation and Function of Ceramide-Enriched Membrane Platforms with CD38 during M1-Receptor Stimulation in Bovine Coronary Arterial Myocytes. *Am J Physiol Heart Circ Physiol* 2008;**295**:H1743-1752.
62. Auge N, Andrieu N, Negre-Salvayre A, Thiers JC, Levade T, Salvayre R. The sphingomyelin-ceramide signaling pathway is involved in oxidized low density lipoprotein-induced cell proliferation. *J Biol Chem* 1996;**271**:19251-19255.
63. Schissel SL, Jiang X, Tweedie-Hardman J, Jeong T, Camejo EH, Najib J *et al.* Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development. *J Biol Chem* 1998;**273**:2738-2746.
64. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. *Circulation* 2007;**116**:1832-1844.
65. Marathe S, Kuriakose G, Williams KJ, Tabas I. Sphingomyelinase, an enzyme implicated in atherogenesis, is present in atherosclerotic lesions and binds to specific components of the subendothelial extracellular matrix. *Arterioscler Thromb Vasc Biol* 1999;**19**:2648-2658.
66. Hojjati MR, Li Z, Zhou H, Tang S, Huan C, Ooi E *et al.* Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. *J Biol Chem* 2005;**280**:10284-10289.
67. Loidl A, Sevcsik E, Riesenhuber G, Deigner HP, Hermetter A. Oxidized phospholipids in minimally modified low density lipoprotein induce apoptotic signaling via activation of acid sphingomyelinase in arterial smooth muscle cells. *J Biol Chem* 2003;**278**:32921-32928.

68.Devlin CM, Leventhal AR, Kuriakose G, Schuchman EH, Williams KJ, Tabas I. Acid sphingomyelinase promotes lipoprotein retention within early atheromata and accelerates lesion progression. *Arterioscler Thromb Vasc Biol* 2008;**28**:1723-1730.

69.Keith M, Geranmayegan A, Sole MJ, Kurian R, Robinson A, Omran AS *et al.* Increased oxidative stress in patients with congestive heart failure. *J Am Coll Cardiol* 1998;**31**:1352-1356.

70.Castro PF, Diaz-Araya G, Nettle D, Corbalan R, Perez O, Nazzari C *et al.* Effects of early decrease in oxidative stress after medical therapy in patients with class IV congestive heart failure. *Am J Cardiol* 2002;**89**:236-239.

71.McMurray J, Chopra M, Abdullah I, Smith WE, Dargie HJ. Evidence of oxidative stress in chronic heart failure in humans. *Eur Heart J* 1993;**14**:1493-1498.

72.Mallat Z, Philip I, Lebreton M, Chatel D, Maclouf J, Tedgui A. Elevated levels of 8-iso-prostaglandin F₂α in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. *Circulation* 1998;**97**:1536-1539.

73.Ng LL, Pathik B, Loke IW, Squire IB, Davies JE. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. *Am Heart J* 2006;**152**:94-101.

74.Tang WH, Tong W, Troughton RW, Martin MG, Shrestha K, Borowski A *et al.* Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. *J Am Coll Cardiol* 2007;**49**:2364-2370.

75.Wong ML, Xie B, Beatini N, Phu P, Marathe S, Johns A *et al.* Acute systemic inflammation up-regulates secretory sphingomyelinase in vivo: a possible link between inflammatory cytokines and atherogenesis. *Proc Natl Acad Sci U S A* 2000;**97**:8681-8686.

76.Grammatikos G, Teichgraber V, Carpinteiro A, Trarbach T, Weller M, Hengge UR *et al.* Overexpression of acid sphingomyelinase sensitizes glioma cells to chemotherapy. *Antioxid Redox Signal* 2007;**9**:1449-1456.

77.Scheel-Toellner D, Wang K, Assi LK, Webb PR, Craddock RM, Salmon M *et al.* Clustering of death receptors in lipid rafts initiates neutrophil spontaneous apoptosis. *Biochem Soc Trans* 2004;**32**:679-681.

- 78.Claus RA, Bunck AC, Bockmeyer CL, Brunkhorst FM, Losche W, Kinscherf R *et al.* Role of increased sphingomyelinase activity in apoptosis and organ failure of patients with severe sepsis. *Faseb J* 2005;**19**:1719-1721.
- 79.Doehner W, Bunck AC, Rauchhaus M, von Haehling S, Brunkhorst FM, Cicoira M *et al.* Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow. *Eur Heart J* 2007;**28**:821-828.
- 80.Anker SD, Volterrani M, Egerer KR, Felton CV, Kox WJ, Poole-Wilson PA *et al.* Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure. *Qjm* 1998;**91**:199-203.
- 81.Zhang DX, Yi FX, Zou AP, Li PL. Role of ceramide in TNF-alpha-induced impairment of endothelium-dependent vasorelaxation in coronary arteries. *Am J Physiol Heart Circ Physiol* 2002;**283**:H1785-1794.
- 82.Clarke CJ, Hannun YA. Neutral sphingomyelinases and nSMase2: bridging the gaps. *Biochim Biophys Acta* 2006;**1758**:1893-1901.
- 83.Krown KA, Page MT, Nguyen C, Zechner D, Gutierrez V, Comstock KL *et al.* Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. *J Clin Invest* 1996;**98**:2854-2865.
- 84.Oral H, Dorn GW, 2nd, Mann DL. Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian cardiac myocyte. *J Biol Chem* 1997;**272**:4836-4842.
- 85.Radin MJ, Holycross BJ, Dumitrescu C, Kelley R, Altschuld RA. Leptin modulates the negative inotropic effect of interleukin-1beta in cardiac myocytes. *Mol Cell Biochem* 2008;**315**:179-184.
- 86.Adam-Klages S, Adam D, Wiegmann K, Struve S, Kolanus W, Schneider-Mergener J *et al.* FAN, a novel WD-repeat protein, couples the p55 TNF-receptor to neutral sphingomyelinase. *Cell* 1996;**86**:937-947.
- 87.Segui B, Cuvillier O, Adam-Klages S, Garcia V, Malagarie-Cazenave S, Leveque S *et al.* Involvement of FAN in TNF-induced apoptosis. *J Clin Invest* 2001;**108**:143-151.

- 88.Liu B, Andrieu-Abadie N, Levade T, Zhang P, Obeid LM, Hannun YA. Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death. *J Biol Chem* 1998;**273**:11313-11320.
- 89.Cailleret M, Amadou A, Andrieu-Abadie N, Nawrocki A, Adamy C, Ait-Mamar B *et al.* N-acetylcysteine prevents the deleterious effect of tumor necrosis factor-(alpha) on calcium transients and contraction in adult rat cardiomyocytes. *Circulation* 2004;**109**:406-411.
- 90.Defer N, Azroyan A, Pecker F, Pavoine C. TNFR1 and TNFR2 signaling interplay in cardiac myocytes. *J Biol Chem* 2007;**282**:35564-35573.
- 91.Bourraindeloup M, Adamy C, Candiani G, Cailleret M, Bourin MC, Badoual T *et al.* N-acetylcysteine treatment normalizes serum tumor necrosis factor-alpha level and hinders the progression of cardiac injury in hypertensive rats. *Circulation* 2004;**110**:2003-2009.
- 92.Adamy C, Mulder P, Khouzami L, Andrieu-abadie N, Defer N, Candiani G *et al.* Neutral sphingomyelinase inhibition participates to the benefits of N-acetylcysteine treatment in post-myocardial infarction failing heart rats. *J Mol Cell Cardiol* 2007;**43**:344-353.
- 93.Kolmakova A, Kwiterovich P, Virgil D, Alaupovic P, Knight-Gibson C, Martin SF *et al.* Apolipoprotein C-I induces apoptosis in human aortic smooth muscle cells via recruiting neutral sphingomyelinase. *Arterioscler Thromb Vasc Biol* 2004;**24**:264-269.
- 94.Auge N, Garcia V, Maupas-Schwalm F, Levade T, Salvayre R, Negre-Salvayre A. Oxidized LDL-induced smooth muscle cell proliferation involves the EGF receptor/PI-3 kinase/Akt and the sphingolipid signaling pathways. *Arterioscler Thromb Vasc Biol* 2002;**22**:1990-1995.
- 95.Tellier E, Negre-Salvayre A, Bocquet B, Itohara S, Hannun YA, Salvayre R *et al.* Role for furin in tumor necrosis factor alpha-induced activation of the matrix metalloproteinase/sphingolipid mitogenic pathway. *Mol Cell Biol* 2007;**27**:2997-3007.
- 96.Coatrieux C, Sanson M, Negre-Salvayre A, Parini A, Hannun Y, Itohara S *et al.* MAO-A-induced mitogenic signaling is mediated by reactive oxygen species, MMP-2, and the sphingolipid pathway. *Free Radic Biol Med* 2007;**43**:80-89.
- 97.Auge N, Maupas-Schwalm F, Elbaz M, Thiers JC, Waysbort A, Itohara S *et al.* Role for matrix metalloproteinase-2 in oxidized low-density lipoprotein-induced activation of the

sphingomyelin/ceramide pathway and smooth muscle cell proliferation. *Circulation* 2004;**110**:571-578.

98.Rizzo V, McIntosh DP, Oh P, Schnitzer JE. In situ flow activates endothelial nitric oxide synthase in luminal caveolae of endothelium with rapid caveolin dissociation and calmodulin association. *J Biol Chem* 1998;**273**:34724-34729.

99.Czarny M, Liu J, Oh P, Schnitzer JE. Transient mechanoactivation of neutral sphingomyelinase in caveolae to generate ceramide. *J Biol Chem* 2003;**278**:4424-4430.

100.Mogami K, Kishi H, Kobayashi S. Sphingomyelinase causes endothelium-dependent vasorelaxation through endothelial nitric oxide production without cytosolic Ca(2+) elevation. *FEBS Lett* 2005;**579**:393-397.

101.Smith AR, Visioli F, Frei B, Hagen TM. Age-related changes in endothelial nitric oxide synthase phosphorylation and nitric oxide dependent vasodilation: evidence for a novel mechanism involving sphingomyelinase and ceramide-activated phosphatase 2A. *Aging Cell* 2006;**5**:391-400.

102.Smith AR, Visioli F, Frei B, Hagen TM. Lipoic acid significantly restores, in rats, the age-related decline in vasomotion. *Br J Pharmacol* 2008;**153**:1615-1622.

103.Tardif JC, Rheume E. Lipoic acid supplementation and endothelial function. *Br J Pharmacol* 2008;**153**:1587-1588.

104.Hernandez OM, Discher DJ, Bishopric NH, Webster KA. Rapid activation of neutral sphingomyelinase by hypoxia-reoxygenation of cardiac myocytes. *Circ Res* 2000;**86**:198-204.

105.Blaustein A, Deneke SM, Stolz RI, Baxter D, Healey N, Fanburg BL. Myocardial glutathione depletion impairs recovery after short periods of ischemia. *Circulation* 1989;**80**:1449-1457.

106.Serviddio G, Di Venosa N, Federici A, D'Agostino D, Rollo T, Prigigallo F *et al.* Brief hypoxia before normoxic reperfusion (postconditioning) protects the heart against ischemia-reperfusion injury by preventing mitochondria peroxyde production and glutathione depletion. *Faseb J* 2005;**19**:354-361.

107.Ramires PR, Ji LL. Glutathione supplementation and training increases myocardial resistance to ischemia-reperfusion in vivo. *Am J Physiol Heart Circ Physiol* 2001;**281**:H679-688.

108.Ozer MK, Parlakpınar H, Cigremis Y, Ucar M, Vardi N, Acet A. Ischemia-reperfusion leads to depletion of glutathione content and augmentation of malondialdehyde production in the rat heart from overproduction of oxidants: can caffeic acid phenethyl ester (CAPE) protect the heart? *Mol Cell Biochem* 2005;**273**:169-175.

109.O'Brien NW, Gellings NM, Guo M, Barlow SB, Glembotski CC, Sabbadini RA. Factor associated with neutral sphingomyelinase activation and its role in cardiac cell death. *Circ Res* 2003;**92**:589-591.

110.Hassoun SM, Lancel S, Petillot P, Decoster B, Favory R, Marchetti P *et al.* Sphingosine impairs mitochondrial function by opening permeability transition pore. *Mitochondrion* 2006;**6**:149-154.

111.Lancel S, Joulin O, Favory R, Goossens JF, Kluza J, Chopin C *et al.* Ventricular myocyte caspases are directly responsible for endotoxin-induced cardiac dysfunction. *Circulation* 2005;**111**:2596-2604.

112.Amadou A, Nawrocki A, Best-Belpomme M, Pavoine C, Pecker F. Arachidonic acid mediates dual effect of TNF- α on Ca²⁺ transients and contraction of adult rat cardiomyocytes. *Am J Physiol Cell Physiol* 2002;**282**:C1339-1347.

113.Keller CD, Rivera Gil P, Tolle M, van der Giet M, Chun J, Radeke HH *et al.* Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling. *Am J Pathol* 2007;**170**:281-292.

114.Bjorkegren J, Silveira A, Boquist S, Tang R, Karpe F, Bond MG *et al.* Postprandial enrichment of remnant lipoproteins with apoC-I in healthy normolipidemic men with early asymptomatic atherosclerosis. *Arterioscler Thromb Vasc Biol* 2002;**22**:1470-1474.

115.Steen H, Kolmakova A, Stuber M, Rodriguez ER, Gao F, Chatterjee S *et al.* MRI visualized neo-intimal dissection and co-localization of novel apoptotic markers apolipoprotein C-1, ceramide and caspase-3 in a Watanabe hyperlipidemic rabbit model. *Atherosclerosis* 2007;**191**:82-89.

116.Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? *Circulation* 2002;**105**:2107-2111.

117.McGovern MM, Pohl-Worgall T, Deckelbaum RJ, Simpson W, Mendelson D, Desnick RJ *et al.* Lipid abnormalities in children with types A and B Niemann Pick disease. *J Pediatr* 2004;**145**:77-81.

118.Marathe S, Miranda SR, Devlin C, Johns A, Kuriakose G, Williams KJ *et al.* Creation of a mouse model for non-neurological (type B) Niemann-Pick disease by stable, low level expression of lysosomal sphingomyelinase in the absence of secretory sphingomyelinase: relationship between brain intra-lysosomal enzyme activity and central nervous system function. *Hum Mol Genet* 2000;**9**:1967-1976.

119.Deigner HP, Claus R, Bonaterra GA, Gehrke C, Bibak N, Blaess M *et al.* Ceramide induces aSMase expression: implications for oxLDL-induced apoptosis. *Faseb J* 2001;**15**:807-814.

120.Andrieu-Abadie N, Jaffrezou JP, Hatem S, Laurent G, Levade T, Mercadier JJ. L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation. *Faseb J* 1999;**13**:1501-1510.

121.Higuchi M, Singh S, Jaffrezou JP, Aggarwal BB. Acidic sphingomyelinase-generated ceramide is needed but not sufficient for TNF-induced apoptosis and nuclear factor-kappa B activation. *J Immunol* 1996;**157**:297-304.

122.Nara F, Tanaka M, Masuda-Inoue S, Yamasato Y, Doi-Yoshioka H, Suzuki-Konagai K *et al.* Biological activities of scyphostatin, a neutral sphingomyelinase inhibitor from a discomycete, *Trichopeziza mollissima*. *J Antibiot (Tokyo)* 1999;**52**:531-535.

123.Luberto C, Hassler DF, Signorelli P, Okamoto Y, Sawai H, Boros E *et al.* Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase. *J Biol Chem* 2002;**277**:41128-41139.

124.Sakata A, Yasuda K, Ochiai T, Shimeno H, Hikishima S, Yokomatsu T *et al.* Inhibition of lipopolysaccharide-induced release of interleukin-8 from intestinal epithelial cells by SMA, a novel inhibitor of sphingomyelinase and its therapeutic effect on dextran sulphate sodium-induced colitis in mice. *Cell Immunol* 2007;**245**:24-31.

125.Levy M, Castillo SS, Goldkorn T. nSMase2 activation and trafficking are modulated by oxidative stress to induce apoptosis. *Biochem Biophys Res Commun* 2006;**344**:900-905.